<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230531058353N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-07</date_registration>
      <primary_sponsor>PNS Shifa</primary_sponsor>
      <public_title>Efficacy of oral itraconazole with sertaconazole cream versus oral itraconazole with clotrimazole cream in dermatophytosis - a randomized controlled trial in a tertiary care hospital in Pakistan</public_title>
      <acronym></acronym>
      <scientific_title>Efficacy of oral itraconazole with sertaconazole cream versus oral itraconazole with clotrimazole cream in dermatophytosis - a randomized controlled trial in a tertiary care hospital in Pakistan</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-06-26</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>118</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70492</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization done by lottery method, in which small chits of paper are kept in a jar and the patients will be asked to pick one deciding their treatment regimen. Half of the chits will be Group A and half of the chits will be Group B. Chits will be folded uniformly to conceal their identity, Blinding description: In this study, the participant, the investigator and outcome assessor were all blinded except for one physician who was supposed to recruit the patients in the group. As explained above, the participants will be asked to pick up a chit of paper from a jar that will be decide in which group they will fall into. Half of the chits will be Group A and half of the chits will be Group B. The chits will be folded uniformly to conceal identity. The participants will not open the chit themselves, but will hand it over to the non-blinded accessor, who will give them the medicine without any label showing the brand or generic name.</study_design>
      <phase>3</phase>
      <hc_freetext>Dermatophyte infection.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In group "A", patients were treated with Tab Itraconazole 100mg twice a day and sertaconazole cream applied topically twice a day for 4 weeks or less in patients in which clinical response is achieved. Intervention 2: Intervention group: In group "B", patients were treated with Tab Itraconazole 100 mg twice a day and clotrimazole cream applied twice a day for 4 weeks or less in which clinical response is achieved.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Primary outcome

When:
1 month after the trial and for lifetime

To whom:
People working in academic institutions

Conditions:
Many

Where to obtain:
abshaabbasi5@gmail.com

How to obtain:
Request

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Absha Abbasi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr Absha Abbasi, 5th floor, OPD Tower, PNS Shifa Hospital</address>
        <city>Karachi</city>
        <country1>Pakistan</country1>
        <zip>74900</zip>
        <telephone>+92 21 48506592</telephone>
        <email>abshaabbasi5@gmail.com</email>
        <affiliation>PNS Shifa</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Absha Abbasi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr Absha Abbasi, 5th Floor, OPD Tower, PNS Shifa Hospital</address>
        <city>Karachi</city>
        <country1>Pakistan</country1>
        <zip>74900</zip>
        <telephone>+92 21 48506592</telephone>
        <email>abshaabbasi5@gmail.com</email>
        <affiliation>PNS Shifa</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients of both, male and female genders, in age group 12-75 years with clinical manifestations of cutaneous dermatophyte infections (tinea corporis/tinea cruris/tinea faciei) and confirmation done with skin scraping positive for potassium hydroxide (KOH) mount.</inclusion_criteria>
      <agemin>12 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with age less than 12 years and greater than 75 years.
Hyperlipidemia
Abnormal liver function tests
Pregnant and breast feeding females.
solitary lesion which is less than 3 cm in diameter
hypersensitivity to antifungals
if patients are on any systemic medications known to have interactions with itraconazole
superadded bacterial infections
patients on immunosuppressive drugs
patients who are known case of liver or renal disease
Tinea capitis and onychomycosis</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>B35</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Dermatophytosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In group "A", patients were treated with Tab Itraconazole 100mg twice a day and sertaconazole cream applied topically twice a day for 4 weeks or less in patients in which clinical response is achieved.</i_keyword>
      <i_keyword>Intervention group: In group "B", patients were treated with Tab Itraconazole 100 mg twice a day and clotrimazole cream applied twice a day for 4 weeks or less in which clinical response is achieved.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Clinical evaluation and absence of fungal hyphae on KOH microscopy. Timepoint: Patients were evaluated clinically on 2 weeks of treatment then 4 weeks of treatment (end point) and then further followed up after 4 weeks. Method of measurement: Clinical evaluation.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>PNS Shifa</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-06-27</approval_date>
        <contact_name>Ethical review committee, PNS Shifa</contact_name>
        <contact_address>PNS Shifa Hospital, DHA Phase 2, Karachi, Pakistan Karachi Sindh Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
